Leoni and IBA enhance accuracy of proton therapy and efficiency in patient workflow

IBA advances its market leading technology via integration of Leoni’s state-of-the-art patient positioning system

Nuremberg, Germany and Louvain-la-Neuve, Belgium – Leoni, the leading European provider of cables and cable systems to the automotive sector and other industries like the healthcare branch, and IBA (Ion Beam Applications S.A.) today jointly announce the availability of a newly advanced patient positioning system configuration from IBA, integrating the Leoni Orion System, a 6 degrees of freedom robot. The Leoni Orion System has been recently granted CE mark, and is currently under 510(k) premarket review process by the FDA.

The Leoni Orion System has key advantages in optimized safety for both patients and radiotherapy staff, while also designed to improve the throughput of patients, thereby increasing the IBA cancer center’s efficiency. Additionally, the Leoni Orion System makes automated positioning adjustments possible in 6 degrees of freedom, to optimize the tumor’s location under the precise IBA proton treatment beam. The Leoni Orion System is integrated both with IBA’s compact single-room Proteus®ONE and with IBA’s multi-room Proteus®PLUS proton therapy solutions.

Intuition and innovation in software and hardware

The Leoni Orion System is fully designed to fulfil medical needs, combining an intuitive software solution with innovative hardware components, thus creating an unprecedented new standard in radiotherapy treatment. It provides multiple benefits, all targeting quick and precise treatment: the system offers several features to decrease the per patient treatment cycle time such as the possibility of preparing the patient outside the treatment room. It provides a dynamic positioning control in six degrees of freedom with sub-millimetre accuracy. Moreover, it features a high patient weight capacity in a large treatment volume. In addition, it installs quickly and easily in new and existing radiotherapy centres. Finally, it is flexible and easy to use, which allows clinical staffs to provide the greatest level of patient care.

Strengthening IBA’s world leading position in proton therapy

Gery Gevers, IBA’s Vice President of Research and Development: “IBA is committed to supporting the research efforts of its multiple partners towards even better treatment deliveries. We are delighted to leverage LEONI’s robotics expertise in advancing the use of our new technology.”

Olivier Legrain, Chief Executive Officer of IBA commented: “Through this collaboration, IBA will further strengthen its world leading position in proton therapy and will reaffirm its leading position in the delivery of the latest innovative cancer therapies worldwide.”

Bruno Fankhauser, member of the Management Board of Leoni AG with responsibility for the Wire & Cable Solutions division states: “We are excited to bring our state of the art industrial technologies and know-how to the medical field, and feel confident that our innovative contribution will support and advance radiotherapy. The collaboration strategically leverages Leoni’s worldwide service and logistics network to support IBA installations in hospitals and cancer clinics around the world. Moreover, the Leoni Orion System is a good example for our company’s innovative power and its development towards being a solution provider.”

How proton therapy improves patient’s quality of life

Proton therapy is a highly precise, targeted cancer radiotherapy treatment. Compared to photons, protons deposit the majority of their effective energy within a precisely controlled range, directly within the tumor, sparing healthy surrounding tissue. This technique offer cancer centres the opportunity to develop new protocols delivering higher doses to the tumor aiming at improved outcome for risk of side-effects, or keeping the same dose but targeting improved patient’s quality of life.